Abstract |
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 - 5; oxaliplatin 130 mg/m2 IV day 2; cytarabine 2000 mg/m2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4. Forty-five eligible patients were accrued between 2006 and 2008. Patient characteristics were a median age of 69 years; 96% had received prior rituximab; 53% were within one year of diagnosis. The median number of cycles received was 2 (range, 1-6). Forty-four % received ROAD as an outpatient. The overall response rate was 71% with 27% (12/45) CR and 44% (20/45) PR. Forty-four % (20/45) of all patients and 69% (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos-not reached) and median progression-free survival was 11 mos (95% CI: 6-104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%. Forty-two percent of all patients and 69% of patients transplanted remain alive at 5 years. ROAD represents an acceptable salvage therapeutic option for patients with relapsed aggressive NHL.
|
Authors | Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, Paul J Kurtin, Levi D Pederson, Dennis F Moore Jr, Nassim H Nabbout, Daniel A Nikcevich, Kendrith M Rowland, Axel Grothey |
Journal | American journal of hematology
(Am J Hematol)
Vol. 92
Issue 10
Pg. 1004-1010
(Oct 2017)
ISSN: 1096-8652 [Electronic] United States |
PMID | 28614905
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | © 2017 Wiley Periodicals, Inc. |
Chemical References |
- Antigens, CD20
- Organoplatinum Compounds
- Recombinant Proteins
- Cytarabine
- Oxaliplatin
- Granulocyte Colony-Stimulating Factor
- pegfilgrastim
- Polyethylene Glycols
- Rituximab
- Dexamethasone
- Filgrastim
|
Topics |
- Aged
- Antigens, CD20
(immunology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Cytarabine
(administration & dosage, adverse effects, therapeutic use)
- Dexamethasone
(administration & dosage, adverse effects, therapeutic use)
- Disease-Free Survival
- Drug Administration Schedule
- Drug-Related Side Effects and Adverse Reactions
(epidemiology, etiology)
- Female
- Filgrastim
- Follow-Up Studies
- Granulocyte Colony-Stimulating Factor
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Kaplan-Meier Estimate
- Lymphoma, B-Cell
(drug therapy, immunology, mortality, pathology)
- Male
- Organoplatinum Compounds
(administration & dosage, adverse effects, therapeutic use)
- Oxaliplatin
- Polyethylene Glycols
- Recombinant Proteins
(administration & dosage, adverse effects, therapeutic use)
- Rituximab
(administration & dosage, adverse effects, therapeutic use)
|